Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Prostate Cancer
DRUG: STM-416p
Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability], Incidence of dose-limiting toxicities (DLTs) over the first 21-days of study treatment, 21 Days|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Incidence of serious adverse events (SAEs), and adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, Time on trial up to 90 days
Pharmacokinetics of STM-416p, Maximum plasma concentration (Cmax) of resiquimod (R848) in patient blood, Day 0, post 24 hours, post 48 hour|Pharmacodynamics of STM-416p in blood circulating cytokines, Pharmacodynamic assessments in plasma and urine will be listed and summarized by dose level, Day 0, post 24 hours, post 48 hours, post 21 days|Assess surgical wound healing, Assessment of wound healing scored according to a modified ASEPSIS method, Day 7, Day 21
A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy